Eli Lilly and Company (LLY)
From Sci-Fi Dream to Market Maze: Eli Lilly's Weight-Loss Medication Faces Hurdles
Founded in Indianapolis in 1876, Eli Lilly and Co. (LLY, Financial) is one of the world's top pharmaceutical companies. Its products are manufactured and distributed in more than 100 countries through facilities in the U.S., Europe and Asia.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Eli Lilly (LLY) Registers a Bigger Fall Than the Market: Important Facts to Note
The latest trading day saw Eli Lilly (LLY) settling at $885.99, representing a -0.61% change from its previous close.
Eli Lilly Has a New Drug That Could Push the Stock Higher
Lilly's Alzheimer's disease drug donanemab could receive FDA approval by year-end. Donanemab would likely be covered by Medicare if approved.
Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
Eli Lilly's Growth Prospects Just Got a Huge Upgrade
Eli Lilly's stock is expensive and is trading at around all-time highs. That's thanks to its promising weight-loss and diabetes drugs, Zepbound and Mounjaro.
Lilly files additional lawsuits over US sales of counterfeit Mounjaro
U.S. drugmaker Eli Lilly on Thursday said it was suing six more U.S. medical spas, wellness centers and other entities for selling products claiming to contain tirzepatide, the active ingredient in its popular diabetes drug Mounjaro.
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.
Eli Lilly Stock Analysis: Buy, Hold, or Sell?
Eli Lilly is ramping up manufacturing to meet the soaring demand for its innovative medicines.
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.
Madrigal Pharmaceuticals is the only company with an approved drug for MASH. Eli Lilly's latest clinical trial data shows that its candidate may perform even better.
Mounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy?
Eli Lilly is developing Mounjaro (tirzepatide) for treating non-alcoholic steatohepatitis. The drugmaker reported positive phase 2 results along those lines earlier this year.
Eli Lilly Scores Another Major Win and Lines Up Its Next Blockbuster
Eli Lilly's potential Alzheimer's treatment looks closer than ever to approval. It could be a nice addition to the pharmaceutical giant's already-deep portfolio.
